Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.

New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia

Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts

CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, announced today that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM. All three events are scheduled alongside the J.P. Morgan 40th Annual Healthcare Conference 2022.

Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P.

Third of Three TSC Oxygenation Trials Third of Three TSC Oxygenation Trials

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

The stock price of Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) increased by over 5% during intraday trading today. This is why it happened.

Diffusion Pharmaceuticals (DFFN) Stock: Why The Price Increased Today

Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523

iBio

Leap Therapeutics

Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility

Second of Three TSC Oxygenation Trials Second of Three TSC Oxygenation Trials

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial

CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the third quarter of 2021 and provided a business update.

Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, will participate in the 2021 Alliance Global Partners Biotech & Specialty Pharma Conference taking place November 10, 2021. Diffusion will also be participating in one-on-one meetings.

Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference

Bellus Health Inc

CytoDyn Inc.

Entera Bio Ltd

With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appeared first on InvestorPlace.

7 Biotech Penny Stocks With Huge Catalysts Coming in 2022

CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, has issued a Letter to Shareholders. The letter provides an update on recent events and outlook for the remainder of 2021 and early 2022.

Diffusion Pharmaceuticals Issues Letter to Shareholders

Conference to Take Place Virtually, September 13-15, 2021 Conference to Take Place Virtually, September 13-15, 2021

Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference

The stock price of Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) increased by over 7% pre-market. This is why it happened.

DFFN Stock: Over 7% Increase Pre-Market Explanation

Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND

Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA's Pulmonology, Allergy, and Critical Care Division

CHARLOTTESVILLE, Va., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the second quarter of 2021 and provided a business update.

Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update

Vinco Ventures

Citius Pharmaceuticals

Powerbridge Technologies Co Ltd

Seanergy Maritime Hlds

Vivos Therapeutics

Weidai Ltd - ADR

Does your list of penny stocks to watch include these 7 hot small-caps? The post Making a List of Penny Stocks to Buy?

Making a List of Penny Stocks to Buy? Here's 7 to Watch in Summer 2021

Senmiao Technology

Ault Global Holdings

Harmony Gold Mining Co Ltd

9 Meters Biopharma

Tellurian

Are these trending penny stocks worth adding to your watchlist? The post 7 Trending Penny Stocks That You Need to Know About in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Trending Penny Stocks That You Need to Know About in July 2021

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) has announced topline results from the Phase 1 trial of its lead product candidate, trans sodium crocetinate (TSC). In the trial, transcutaneous oxygen monitoring (TCOM) was used to measure the direct pharmacodynamic effects of TSC on peripheral tissue oxygenation in healthy volunteers.

Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation

Trial Dosed Healthy Volunteers with Trans Sodium Crocetinate Trial Dosed Healthy Volunteers with Trans Sodium Crocetinate

Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial

Presentation Scheduled for June 24, 2021 at 11:30 a.m., EDT Presentation Scheduled for June 24, 2021 at 11:30 a.m., EDT

Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum

Annual Meeting Scheduled for June 25, 2021, at 1 p.m. EDT Annual Meeting Scheduled for June 25, 2021, at 1 p.m. EDT

Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual Meeting

GEE Group

Hot Penny Stocks Under $1 To Watch This Month The post Best Penny Stocks Today? 4 Small-Cap Stocks To Watch Under $1 In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks Today? 4 Small-Cap Stocks To Watch Under $1 In June

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) has announced final results from the Phase 1b study evaluating trans sodium crocetinate (TSC) in hospitalized COVID-19 patients. Data from the open-label study were reviewed by an independent Safety Monitoring Committee (SMC).

Diffusion Pharma's Trans Sodium Crocetinate Associated With Improved Outcomes In COVID-19 Patients

CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced final results from the Phase 1b study evaluating trans sodium crocetinate (TSC) in hospitalized COVID-19 patients.   Data from the open-label study were reviewed by an independent Safety Monitoring Committee (SMC).

Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients

CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the first quarter of 2021 and provided a business update.

News for Diffusion Pharmaceuticals Stock (DFFN)